Verastem (VSTM) Cash from Operations Growth (1y) (2012 - 2026)
Verastem (VSTM) Cash from Operations Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,880.51 Bn | 1,880.45 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.94 Bn | 463.15 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.63 Bn | 115.38 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.30 Bn | 61.54 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.81 Bn | 62.81 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.59 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 158.60% |
| 10 | Verastem | 619.24 Mn | 421.41 Mn | 15.90 Mn | -34.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.75% |
| Dec 31, 2025 | -19.34% |
| Sep 30, 2025 | -52.20% |
| Jun 30, 2025 | -18.47% |
| Mar 31, 2025 | -36.63% |
| Dec 31, 2024 | 15.44% |
| Sep 30, 2024 | -43.44% |
| Jun 30, 2024 | -38.51% |
| Mar 31, 2024 | -39.54% |
| Dec 31, 2023 | -78.63% |
| Sep 30, 2023 | -9.99% |
| Jun 30, 2023 | -56.80% |
| Mar 31, 2023 | -5.21% |
| Dec 31, 2022 | -67.28% |
| Sep 30, 2022 | -39.30% |
| Jun 30, 2022 | 5.44% |
| Mar 31, 2022 | 0.19% |
| Dec 31, 2021 | 54.23% |
| Sep 30, 2021 | -124.20% |
| Jun 30, 2021 | 40.46% |